To all, here's the text of THRX's earnings report:
BW1176 JUL 23,1996 6:23 PACIFIC 09:23 EASTERN
( BW)(THERAGENICS)(THRX) Theragenics Corp. reports revenue and
earnings for second quarter 1996
Business Editors & Medical Writers
ATLANTA--(BUSINESS WIRE)--July 23, 1996--Theragenics Corp.
(NASDAQ:THRX), the Atlanta based cancer treatment producer,
today announced revenues and earnings for the second quarter ending
June 30, 1996.
Revenues for the quarter were $2,726,535 compared to
$1,911,647, a 43 percent growth over the same period last year. Net
income increased 76 percent to $677,799 from $384,893 with earnings
per share improving to $0.06 versus $0.03 in the prior year.
For the six months ended June 30, 1996, revenues were $5,524,891
versus $3,746,109, a 47 percent improvement over the first six
months last year. Net income grew 100 percent to $1,531,976 from
$766,503 with earnings per share of $0.13 versus $0.07.
Commenting on the quarter Christine Jacobs, president and CEO,
said, "Theragenics' commitment to build on its history of profitable
operations continues to be in evidence. The expansion of our
cyclotron facility is completed and is ready to accept cyclotrons
three and four. Cyclotron number three was delivered safely and
installation has commenced. Cyclotron four is scheduled to be
delivered by year end and in production by the second quarter of
1997. The completion of these two installations doubles our plant
and capacity.
"Theragenics continues to experience increased interest from
patients and doctors alike. This interest is in part a result of
recent coverage by both the television and print media spotlighting
prostate cancer and seed implantation as an alternative treatment for
this devastating disease," Jacobs continued.
Theragenics Corp., based in Norcross, Ga., is the manufacturer
of TheraSeed(R), a rice-sized device used in the treatment of
localized prostate cancer with a one-time, minimally-invasive
procedure. For additional information on the Company, call
Theragenics' Investor Relations Department at (800)998-8479. The
Company's common stock is traded on the NASDAQ stock exchange under
the symbol THRX.
-0-
*T
Theragenics Corporation
Consolidated Statement Of Operations
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
1996 1995 1996 1995
Revenues $2,726,535 $1,911,647 $5,524,891 $3,746,109
Net Income $ 677,799 $ 384,893 $1,531,976 $ 766,503
Earnings Per
Common Share $ 0.06 $ 0.03 $ 0.13 $ 0.07
Weighted Average
Shares Outstanding 12,203,945 11,783,995 12,170,261 11,745,723
*T
--30--hc/at*
CONTACT: Theragenics Corp.
Ron Warren, (800)998-8479
|
